Does human papillomavirus cause pterygium?

British Journal of Ophthalmology

Volumn 87, Issue 7, 2003, Pages 806-808

  Reid, Ted W ^a   Dushku, N ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

CANCER INVASION; CARCINOMA IN SITU; CATARACT EXTRACTION; CONJUNCTIVA EPITHELIUM; DISEASE ASSOCIATION; EDITORIAL; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; KERATOPATHY; PRIORITY JOURNAL; PTERYGIUM; RISK ASSESSMENT; SCAR FORMATION; SQUAMOUS CELL CARCINOMA; VIRUS INFECTION; WART VIRUS;

HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PTERYGIUM; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 0037784234     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.7.806     Document Type: Editorial

References (29)

1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002;2:342-350.
2. Schwartz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus type 18 and 16 sequences in cervical carcinoma cells. Nature 1985;314:111-114.
3. Durst M, Dzarlieva-Petrusevska RT, Boukamp P, et al. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1987;1:251-6.
4. Pirsi L, Yasumota S, Fellery M, et al. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987;61:1061-6.
5. Von Knebel Doeberitz M, Rittmuller C, zur Hausen H, et al. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA. Int J Cancer 1992;51:831-4.
6. Von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, et al. Reversible repression of papillomavirus oncogenes expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRb interactions. J Virol 1994;68:2811-21.
7. Munoz N, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Columbia and Spain. Int J Cancer 1992;52:743-9.
8. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBXCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
9. Zur Hausen H. Papillomavirus infections B a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-78.
10. Kessis TD, Slebos RJ, Nerson WG, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90:3988-92.
11. Foster SA, Demers GW, Etscheid BG, et al. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994;68:5698-705.
12. Aguilar-Lemarroy A, Garglio P, Whitaker NJ, et al. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002;21:165-75.
13. Barten M, Ostwald C, Milde-langosch K, et al. HPV DNA and p53 alterations in oropharyngeal carcinomas. Virchows Arch 1995;427:153-7.
14. Lam KY, Chan,AC, Chan KW, et al. Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Eur J Surg Oncol 1995;21:613-16.
15. Akasofu M, Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virchows Arch 1995;425:593-602.
16. Dushku N, Reid TW. p53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997;16:1179-92.
17. Gallagher MJ, Giannoudis A, Herrington CS, et al. Human papilloma virus in pterygium. Br J Ophthalmol 2001;85:782-4.
18. Detorakis ET, Sourvinos G, Spandidos DA. Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium. Cornea 2001;20:164-7.
19. Dolmetsch AM, Alcocedr CE, Scull JJ, et al. The presence of human papillomavirus in pterygia. Invest Ophthalmol Vis Sci (abstract) 1996;37:S43.
20. McDonnell JM, McDonnell PJ, Sun YY. Human papillomavirus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasia. Invest Ophthalmol Vis Sci 1992;33:184-9.
21. Dushku N, Hatcher S, Albert DM, et al. p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors. Arch Ophthalmol 1999;117:1593-9.
22. Karcioglu ZA, Issa TM. Human papillomavirus in neoplastic and nan-neoplastic conditions of the external eye. Br J Ophthalmol 1997;81:595-8.
23. Zhou J, Sun XY, Stenzel DJ, et al. Expressian of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7.
24. Zhang LF, Zhou J, Chen S, et al. HPV 6b virus like particles are potent immunagens without adjuvant in man. Vaccine 2000;18:1051-8.
25. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
26. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
27. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
28. Maskin SL. Regression of limbal epithelial dysplasia with topical interferon [letter]. Arch Ophthalmol 1994;112:1145-6.
29. Fung-Rong H, Ming-Jet W, Sow-Hsong, K. Interferon treatment for corneolimbal squamous dysplasia. Am J Ophthalmol 1998;125:118-119.